Search Results

Results for Pharmaceutical:

Noubar Afeyan

Noubar Afeyan

Department: Senior Lecturer, Martin Trust Center for MIT Entrepreneurship

Contact: (617) 868-1888, nafeyan@mit.edu

Expertise: International entrepreneurship

Thomas J Allen

Thomas J Allen

Howard W. Johnson Professor of Management, Emeritus

Department: Professor of Organization Studies

Contact: (617) 253-6651, tallen@mit.edu

Expertise: Engineering management; Pharmaceuticals

Pierre Azoulay

Pierre Azoulay

Sloan Distinguished Associate Professor of Technological Innovation, Entrepreneurship, and Strategic Management

Contact: (617) 258-9766, pazoulay@mit.edu

Expertise: Alliances; Applied microeconomics; Apps; Biopharmaceutical; Biotechnology; Clinical trials; Cloud computing; Cloud storage; Competitive strategy; Corporate strategy and policy; Employee motivation; Hi technology companies; Incentives; Innovation; Innovation management; Innovative thinking; Intellectual property; Intellectual property; Intellectual property law; Intellectual property laws; Labor market policy; Mergers and acquisitions; MOOCs; MOOCs; Non-market strategy; Online education; Outsourcing; Patents; Pharmaceuticals; Product innovation; Research and development; Startups / Start-ups; Strategy; Technological innovation; Technology strategy; Technology transfer; Technology transfer; Twitter; Yelp

Ernst Berndt

Ernst Berndt

Louis E. Seley Professor in Applied Economics

Department: Professor of Applied Economics

Contact: (617) 253-2665, eberndt@mit.edu

Expertise: Affordable Care Act (ACA); Applied economics; Applied microeconomics; Applied probability; Biopharmaceutical; Biotechnology; Cancer; Clinical trials; Data analytics; Drug models; Econometrics; Economics; Education; Game theory; Health management; Healthcare; Healthcare industry; HIV; Industrial organization; Industrial organization; Industrial partnerships; Institutional partnerships; Intellectual property; Intellectual property; Intellectual property law; Market research; Medicaid; Medical decision making; Medical devices; Medicare; Medicine; Microeconomics; Outsourcing; Pharmaceuticals; Pricing; Regulation and policy; Sampling; Statistics; Stochastic modeling

Zen Chu

Zen Chu

Department: Senior Lecturer

Contact: (617) 699-4036, zenven@mit.edu

Expertise: Accelerators; Action learning; Affordable Care Act (ACA); Alibaba; Alibaba; Alliances; Angel investing; Apple; Apps; Asia; Asia Pacific; B-school; Big data; Biopharmaceutical; Biotechnology; Business education; Cancer; China; Clinical trials; Cloud computing; Cloud storage; Competitive strategy; Conflicts of interest; Conflicts of interest; Consumer electronics; Convergence; Corporate social responsibility; Cross-cultural awareness; Crowdfunding; Cultural differences; Cyber security; Developing countries; Developing countries, economics; Digital economy; Digitization; eBusiness; eCommerce; eGovernment; Electronic commerce; Electronic media; Emerging businesses; Emerging markets; Entrepreneurial finance; Entrepreneurial finance; Entrepreneurial management; Entrepreneurship; Executive education; Genetics; Genome; Global entrepreneurship; Global entrepreneurship; Hacking; Healthcare; Healthcare delivery; Healthcare operations management; Hi-technology / Hi-tech; Hospital operations management; Incubators; India; Information technology; Innovation; Innovation management; Innovative thinking; Insurance; Intellectual property; International corporate strategy; International entrepreneurship; Internet applications; Internet security; Internet software; Internet strategy; Internet telephony; iPhone; Knowledge management; Knowledge sharing; Lead users; Lead users; Leadership; Leadership; Medical decision making; Medical devices; Medical devices; Medicare; Medicine; Mergers and acquisitions; MOOCs; Multi-drug models; Nanotechnology; New venture development; New ventures; Obamacare; Open innovation; Open source software; Patents; Pharmaceuticals; Predictive analytics; Private equity; Privatization; Product design; Product development; Product innovation; Research and development; Silicon Valley; Silicon Valley; Singapore; Smartphones; Social entrepreneurship; Social networks; Social responsibility; Software; Southeast Asia; Startups / Start-ups; Strategic management; Strategic planning; Strategy; Taiwan; Technological innovation; Technological innovation; Technological innovation; Technology strategy; Technology transfer; Technology transfer; Telecommunications; Thailand; United States; Venture capital; Venture capital; Vietnam; Virtual customer; Web-based marketing; Wireless communication; X-teams

John Grant

John Grant

Department: Senior Lecturer, International Action Learning Programs (G-Lab, China/India Lab, GO-Lab)

Contact: (617) 324-4373, jcgrant@mit.edu

Expertise: Action learning; Asia; Biopharmaceutical; Biotechnology; China; Competitive strategy; Corporate diversification; Corporate finance; Corporate finance; Corporate strategy and policy; Cross-cultural awareness; Forecasting; France; Germany; Global business practices; Global business processes; Global entrepreneurship; Global entrepreneurship; Healthcare; India; International corporate strategy; International corporate strategy; International finance; International management; Japan; Medical devices; Medical devices; Mergers and acquisitions; New venture development; Performance measurement systems; Pharmaceuticals; Southeast Asia; Strategic management; Strategic planning; Strategy; Taiwan; United Kingdom; United States; Valuation; Valuation; Vietnam

Christopher Knittel

Christopher Knittel

William Barton Rogers Professor of Energy

Department: Professor of Applied Economics

Contact: (617) 324-0015, knittel@mit.edu

Expertise: Alternative energy; Applied economics; Applied microeconomics; Bank regulation; Banking; Banking industry; Banking regulation; Carbon footprint; Clean coal; Clean energy; Climate change; Climate policy; Coal; Competitive strategy; Computational economics; Consumer behavior; Corporate strategy and policy; Credit card industry; Data analytics; Drought; Econometrics; Econometrics; Economics; Economy; Electricity; Emissions trading; Emissions trading; Energy; Energy Economics; Energy efficiency; Energy finance; Environment; Environmental Economics; Environmental policy; Ethanol; Financial econometrics; Fracking; Gas; Global climate change; Global warming; Hydraulic fracturing; Industrial economics; Industrial Organization; Industrial organization; Managerial economics; Mergers and acquisitions; Microeconomics; Natural gas; Nonlinear optimization; Nuclear power; Oil; Oil industry; Optimization; Outsourcing; Outsourcing; Pharmaceuticals; Pricing; Product loyalty; Public utilities; Regulatory bodies; Solar power; Sports analytics; Subsidies; Sustainability; Tax reforms; Water; Wind power

Andrew Lo

Andrew Lo

Charles E. and Susan T. Harris Professor

Department: Professor of Finance

Contact: (617) 253-0920, andrew.lo@mit.edu

Expertise: Analyst forecasts; Angel investing; Applied economics; Applied mathematics; Applied probability; Arbitrage pricing theory; Artificial intelligence; Asset management; Asset pricing; Banking; Banking management; Banking operations and policy; Banking regulation; Bankruptcy; Bayesian networks; Bayesian statistics; Bayesian statistics; Big data; Biopharmaceutical; Biotechnology; Bond markets; Bond negotiations; Bond pricing; Business intelligence; Business plans; Cancer; Capital budgeting; Capital controls; Capital market; CEO compensation; Clinical trials; Consumer behavior; Contagion; Corporate diversification; Corporate finance; Corporate governance; Corporate strategy and policy; Currency; Cyber security; Data acquisition; Data analysis; Data mining; Decision making; Deflation; Derivatives; Disaster recovery; Distance learning; Dividend policy; Dot-com; Drug models; eCommerce; Econometrics; Economic crisis; Economics; Education; Emerging businesses; Entrepreneurial finance; Entrepreneurial management; Equities; Euro; Exchange rates; Executive compensation; Federal Reserve; Financial econometrics; Financial engineering; Financial information technology; Financial information technology; Financial markets; Financial reporting; Financial services; Financial statement analysis; Foreign investment; Futures; Government; Healthcare; Healthcare industry; Hedge funds; Hurdle rates; Inflation; Intellectual property; Intellectual property law; Interest rates; International finance; Internet privacy issues; Intertemporal choice; Investment analysis; Investment banking; Investment risk; Investment strategies; Knowledge sharing; Macroeconomics; Mathematical programming; MBA; Medical decision making; Medicine; Mergers and acquisitions; Mobile banking; MOOCs; Mortgage funds; Mutual funds; Neural networks; New venture development; New ventures; Non-linear dynamics; Online banking; Online education; Online feedback mechanisms; Operations research; Optimal control; Optimization; Options; Patents; Pensions; Personal finance; Pharmaceuticals; Portfolio choice; Portfolio design and management; Private equity; Research and development; Retirement planning; Revenue management; Risk capital; Risk management; Sampling; Securities and Exchange Commission (SEC); Security prices; Simulation; Software agents; Startups / Start-ups; Statistics; Stochastic modeling; Stock exchange; Stock exchange consolidation; Stock market; Stock options; Stock trading; Subprime lending; Trading decisions; Treasuries; Venture capital; Wall Street; Web-based marketing

Stewart Myers

Stewart Myers

Robert C. Merton (1970) Professor of Financial Economics

Department: Professor of Finance

Contact: (617) 253-6696, scmyers@mit.edu

Expertise: Banking; Corporate finance; Finance; Insurance; Pharmaceuticals

John Parsons

John Parsons

Department: Senior Lecturer / MBA Program Finance Track Head

Contact: (617) 324-3745, jparsons@mit.edu

Expertise: Capital budgeting; Climate policy; Corporate diversification; Corporate finance; Corporate strategy and policy; Derivatives; Dividend policy; Emissions trading; Energy; Environment; Environmental economics; Environmental policy; Finance; Financial engineering; Financial markets; Gas; Hurdle rates; Nuclear power; Oil; Public utilities; Risk management; Securities and Exchange Commission (SEC)

Robert Pindyck

Robert Pindyck

Bank of Tokyo-Mitsubishi Ltd Professor in Finance and Economics

Department: Professor of Applied Economics

Contact: (617) 253-6641, rpindyck@mit.edu

Expertise: Alternative energy; Antitrust; Applied economics; Applied microeconomics; Climate change; Climate policy; Derivatives; Energy; Energy economics; Energy efficiency; Energy finance; Environment; Environmental economics; Environmental policy; Gas; Global climate change; Global warming; Industrial economics; Industrial organization; Investment analysis; Investment policy; Managerial economics; Microeconomics; Natural gas; Optimal control; Optimization; Options; Options pricing valuation; Sustainability

Edward Roberts

Edward Roberts

David Sarnoff Professor of Management of Technology

Contact: (617) 253-4934, eroberts@mit.edu

Expertise: Angel investing; Angel investing; Emerging businesses; Entrepreneurship; Global entrepreneurship; Global entrepreneurship; Hi technology companies; Hi-technology / Hi-tech; Innovation; Innovation management; Management of technology; New venture development; New ventures; Research and development; Social entrepreneurship; Startups / Start-ups; Technological innovation; Technological innovation; Technology transfer; Venture capital; Venture capital

Henry Weil

Henry Weil

Department: Senior Lecturer, Technological Innovation, Entrepreneurship, and Strategic Management

Contact: (617) 258-6101, hbweil@mit.edu

Expertise: Airlines; Alliances; Asia; Aviation; Banking; Bermuda; Business process modeling; Capital budgeting; China; Competition; Competition; Competitive strategy; Computer industry; Consumer behavior; Convergence; Corporate strategy and policy; Credit card industry; Customer relationships; Customer service; Data acquisition; Digitalization; Dot-com; eCommerce; Electronic media; Emerging businesses; Emerging markets; Energy; Entrepreneurial management; Ethanol; Europe; European Union (EU); Financial services; France; Globalization; Hong Kong; Industrial economics; Information technology; Innovation; International corporate strategy; International management; Internet telephony; Lead users; Management of technology; Marketing strategy; Media; Microeconomics; Mobile computing; New ventures; Nonlinear dynamics; Oil; Online banking; Online media; Pharmaceuticals; Pricing; Research and development; Retirement planning; Singapore; Startups / Start-ups; Strategic management; Strategic planning; System dynamics; Taiwan; Technological innovation; Technological strategy; Technological transfer; Trust-based marketing; Wi-Fi; Wireless communication

Andrey Zarur

Andrey Zarur

Department: Lecturer, Martin Trust Center for MIT Entrepreneurship

Contact: (781) 684-0239, azarur@mit.edu

Expertise: Biopharmaceutical; Biotechnology; Business plans; Climate policy; Clinical trials; Emerging businesses; Energy; Entrepreneurial management; Environment; Global climate change; Global warming; Healthcare; Innovation; Medical devices; Mexico; Multi-drug models; New ventures; Pharmaceuticals; Research and development; Startups / Start-ups; Venture capital

Can current investment in new drugs be sustained? — Ernst Berndt

From Pharmaceutical Manufacturing When blockbuster drugs hit the market, they make big news and big profits. But for every blockbuster drug launched, there are an awful lot of disappointments. A good example is Vertex’s launch of the Hepatitis C drug Incivek. It was extremely successful in its first year on the market and heralded in a new era of Hepatitis C therapies. However, that meant competition. It wasn’t too long before newer and better treatments like Gilead’s Sovaldi and AbbVie’s Viekira Pak essentially replaced it in the market. Last spring, Vertex announced that not only is it no longer investing in research or developing new Hepatitis C drugs, it was withdrawing Incivek from the market. Even when we see tremendous therapeutic progress with a drug potentially worth billions, there is the risk that it will be overtaken by the next generation of drugs. There is no sure thing. Prior research … Read More »The post Can current investment in new drugs be sustained? — Ernst Berndt appeared first on MIT Sloan Experts.

Your Recent Searches

Can't find what
you're looking for?

Contact us.

Twitter

Paul Denning
Director of Media
Relations
617.253.0576
denning@mit.edu

Patricia Favreau
Associate Director of
Media Relations
617.253.3492
pfavreau@mit.edu

©2010 MIT Sloan School of Management